* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download disease genes
History of genetic engineering wikipedia , lookup
Medical genetics wikipedia , lookup
Tay–Sachs disease wikipedia , lookup
Nutriepigenomics wikipedia , lookup
Metagenomics wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Minimal genome wikipedia , lookup
Human genome wikipedia , lookup
Gene expression profiling wikipedia , lookup
Pathogenomics wikipedia , lookup
Site-specific recombinase technology wikipedia , lookup
Behavioural genetics wikipedia , lookup
Gene therapy of the human retina wikipedia , lookup
Neuronal ceroid lipofuscinosis wikipedia , lookup
Biology and consumer behaviour wikipedia , lookup
Microevolution wikipedia , lookup
Genome evolution wikipedia , lookup
Human genetic variation wikipedia , lookup
Epigenetics of neurodegenerative diseases wikipedia , lookup
Designer baby wikipedia , lookup
Genome (book) wikipedia , lookup
“10,001 Dalmatians” research programme: Discovery of genetic variants that control human quantitative traits and predispose to diseases Igor Rudan, Mladen Boban, Tatijana Zemunik, Gordan Lauc, Zoran Đogaš, Stipan Janković, Ivica Grković, Ana Marušić, Janoš Terzić, Rosanda Mulić, Vjekoslav Krželj, Lina Zgaga, Zrinka Biloglav, Ivana Kolčić, Marina Pehlić, Grgo Gunjača, Danijela Budimir, Ozren Polašek 2001. – human genome sequence was published Main expectation (general public, investors, researchers, pharma and biotech industries): Linking genes with diseases and development of new treatments and “personalized medicine” – the race towards this goal begun (each group with its own approach) Main idea: 1) Find “markers” in the genome and “tag” the whole genome as densely as possible; 2) Find consistent associations between some of those markers and disease phenotypes 3) Find genes in proximity of implicated markers – they are “disease genes” CASES (“affected”) CONTROLS (“unaffected”) STR MARKER A STR MARKER B,C… DISEASE GENE (MUTATION) DISEASE GENE (WILD TYPE) Short tandem repeats (STR) – e.g. (TA)x4 or (CTG)x7 – hundreds of STRs across the genome - STR marker maps were not dense, but they were still very useful to “pick” genes that caused monogenic (Mendelian) diseases Problems with genome-wide linkage analyses using genome-wide STR maps: 1) STR markers and diseases were not always 100% linked because of incomplete penetrance of causing mutations or genetic heterogeneity of the disease: low study power 2) STR markers and disease genes were not always 100% linked because of recombination (crossing over) between them: low study power CASES (“affected”) CONTROLS (“unaffected”) STR MARKER A STR MARKER B,C… DISEASE GENE (MUTATION) DISEASE GENE (WILD TYPE) Problems with genome-wide linkage analyses using genome-wide STR maps: 3) Even when a marker closest to disease gene was found with nearly 100% certainty, it still took years to find all candidate genes in regions up to 10 megabases (or more) and sequence them all to find exact causal mutation 4) Good ideas: - - Choose to study phenotypes that are precisely measurable and in good correlation with genotypes Use populations with large linkage disequilibrium Strategy (1): Our group proposed to rely on isolated populations (for increased LD) and pedigree-based approach (adds information) in 1999 Nat Genet 1999; 23: 397-404 Strategy (2): Our group proposed a highly polygenic model for complex traits and diseases in 2003 Genetics 2003; 163: 1011-1021 Trends Genet 2003; 19: 97-106 Our understanding of complex traits and diseases: COMPLEX DISEASE PHENOTYPE ENVIRONMENT QUANTITATIVE TRAIT LEVEL (e.g. CHOLESTEROL, BLOOD PRESSURE) ENVIRONMENT “-OMICS” LEVEL (PROTEOMICS, LIPIDOMICS, GLYCOMICS, METABOLOMICS) ENVIRONMENT GWAS: MOST POWER & FUNCTIONAL RELEVANCE HIGHLY POLYGENIC GENETIC BASIS (FEW RARE VARIANTS WITH LARGE EFFECTS AND MANY COMMON WITH SMALL EFFECTS) Strategy (3): Our group proposed to measure large number of QTs (closer to genes - power, more chance, later - networks) Quantitative traits: More than 100 selected initially ANTHROPOMETRIC MEASURES PHYSIOLOGICAL MEASURES ELECTROCARDIOGRAM Body height Systolic blood pressure (1&2) ECG (30 sec, digital)* Body weight Diastolic blood pressure (1&2) P duration Bicondylar brachial width Impedance - body resistency PR interval Abdomen circumference Impedance - body reactancy QRS duration Hip circumference Ankle-brachial BP indeks QT interval Brachial circumference Spirometry - FVC QTc interval Biceps skinfold Spirometry - FEV1 P axis Triceps skinfold Spirometry - PEF QRS axis Subscapular skinfold Spirometry - FEF25 T axis Suprailiac skinfold Spirometry - FEF50 Abdomen skinfold Peak flow Head circumference Bone mineral density COGNITIVE & SLEEP TRAITS EYE MEASURES LIFESTYLE Eysenck Personality Inventory Retinal art:ven diameter ratio Family disease history Digit-symbol test Retinal art leng:diam ratio Birth weight Mill-Hill vocabulary Retinal art branching angle Medical/surgical history Standard Progress. Matrices Retinal arteriolar tortuosity Menstruation, menarche, HRT Controlled Oral Word Assoc. Retinal arterjunction expon Rose Angina questionnaire* Weschler Memory Scale Intraoccular pressure, OD, OS Claudication questionnaire* Munich Chronotype Question. Fundus photography Respiratory questionnaire GHQ-30 Autorefractor-measurements Physical activity Intra-ocular length-measur. Smoking Alcohol Diet Socioeconomic status Quantitative traits: More than 100 selected initially BIOCHEMICAL MEASURES Creatinine Uric acid Total cholesterol Triglycerides HDL LDL Calcium Phosphorous Albumin LIPIDOMICS MARKERS OF INFLAMMATION lipid metabolytes, e.g. Fibrinogen von Willebrand's factor D-dimers 132 phospholipids, CRP 70 sphingolipids, fatty acids, tPA inhibitor A large number (several hundred) of circulating apolipoproteins, etc. HbA1c Glucose GLYCOMICS URINE TRAITS GENOTYPING 16 main groups of N-glycans, A larger number of traits Cohort 1: STR typing 4 additional groups based on quantitated in urine samples Cohort 2: 800 STR number of antennas, and that are biomedically 3 derived variables relevant 317.000 SNP Cohort 3: 370.000 SNP + CNV Cohort 4: 370.000 SNP + CNV Strategy (4): Finding money to start a large cohort Grants awarded 2000-2007 (£ 4.0 M) 2000-2002: The British Council 2001-2004: The Wellcome Trust 2002-2003: Medical Research Council UK (1/3) 2002-2006: Ministry of Science and Technology, Croatia 2003-2005: The Royal Society, UK 2003-2004: National Institutes of Health, USA 2003-2005: Medical Research Council UK (2/3) 2006-2009: EU fp6 EUROSPAN 2005-2010: Medical Research Council UK (3/3) 2007-2012: Ministry of S & T, Croatia (The Croatian Biobank) COHORT 1. (1001 examinee) “Susak-10”: served to choose the most appropriate population (2001-2002) 2003: The choice of further populations was based on demography data and population genetic studies 2003: The populations were extremely differentiated (based on analysis of 26 STR markers below); LD studies conducted using 8 STR markers on Xq13-12 COHORT 2. (1024 examinees) “Vis”: genotyped with (i) 800 STRs and (ii) Illumina 317 k (2003-2005) COHORT 3. (969 examinees) “Korcula”: genotyped with Illumina 370 k CNV (2006-2007) COHORT 4. (1001 examinees) “Split”: outbred population genotyped with Illumina 370 k CNV (2008-2009) Year 2005: BAD YEAR We used 800 STR marker scan and analysed the data using genome-wide linkage analysis. What did we find? ABSOLUTELY NOTHING. Other approaches (e.g. candidate genes and case-control studies)? NO REPLICATIONS FOR ANY OF THE THOUSANDS OF REPORTED ASSOCIATIONS (…OK, MAYBE 4-5 MAX.) The HapMap project Tried to define “blocks” of genome between “recombination hotspots” and tag each one of them with one of more than 10 million predicted SNPs: new GWAS based on SNPs Year 2006: TECHNOLOGICAL BREAKTHROUGH! Affymetrix Inc. and Illumina Inc.: Dense genome-wide scans using hundreds of thousands of SNP markers (from HapMap project – “tagging SNPs) Year 2007: THE “BRAVE NEW WORLD” STUDY (WTCCC, Nature, June 07, 2007) 2006.-2007. First analyses of data using SNP Results of GWAS of QTs with “disease risk” studied Nat Genet 2008; 40: 437-442 Nat Genet 2009; 41: 47-55 2008: uric acid & gout 2009: lipid levels & coronary heart disease 2010: fasting glucose & diabetes type 2 Nat Genet 2010 2010: FVC, FEC & chr. lung disease Nat Genet 2010 2010: creatinine & chr. kidney disease Nat Genet 2010 (2011: blood pressure & stroke) JAMA 2011 ? (2011: CFH & age-related mac. degeneration) Lancet ? Results of GWAS of QTs without disease risk links PLoS Genet 2009; 5: e1000504 PLoS Genet 2009; 5: e1000539 2009: smoking initiation and intensity Nat Genet 2010 2009: clotting factors VII, VIII & vWF Circulation 2010 (2010: sleep duration and latency) Nat Genet 2010 ? (2010: human height, weight, WHR) 3 x Nat Genet 2010 ? (2010: global lipids) Nature 2010 ? (2010: cognitive traits) 2 x Nat Genet 2010 ? (2010: ECG, urine, CRP, HbA1c, ABPI, P, cortisol…) Strategy (5): Next moves (plan for 2010-2012) 1. GWAS of -OMICS (“1 level down from QT”) & functional follow-up & systems biology / pathways 2. Development of novel methods for analysis of the effect of CNV and rare variants on human QTs 3. Expand the number of phenotypes measured in plasma in at least 3,000 examinees (e.g. ILs, etc.) 4. Whole-genome sequence for 1,000 examinees & the new round of consortia participation Results of GWAS of LIPIDOMICS traits PLoS Genet 2009; 163: 1011-1021 Forthcoming (2010): GWAS of 132 circulating phospholipids (PLoS Genetics) Further interest of our group: GWAS of glycomics, proteomics, other metabolomics and functional follow-up Progress in GLYCOMICS: dependent of measurement Rudd PM et al. (Natl. Inst. Bioprocessing Res. Train.): refined chromatography approaches for analysis of glycosylation High-performance liquid chromatography (HPLC): - Glycoproteins immobilized - Glycans released - Fluorescent labels attached - Labelled sugars run on a normal phase HPLC column - Resulting peaks correlated to a pre-run dextran ladder Nature 2009; 457: 617-620 CROATIAN CENTRE FOR GLOBAL HEALTH “GlycoBioGen”: A consortium led by collaboration of Scottish, Croatian & Irish institutions Quantitation of glycans in human plasma: J Proteome Res 2009; 8: 694-701 • Separation of plasma N-glycans in 16 chromatographic peaks using HPLC method (GP1-GP16): area under peak measured as a QT • Unusual biological variability at population level • Significant effects of age, gender, environmental factors • Highly varying heritabilities • Striking correlations with other biochemical QTs Results of GWAS study (Vis island, Croatia): • FUT8: associated with GP1 in 1,000 subjects (p=5.09 x 10-8 - 7.07 x 10-8) Strategy (5): Next moves (plan for 2010-2012) 1. GWAS of -OMICS (“1 level down from QT”) & functional follow-up & systems biology / pathways 2. Development of novel methods for analysis of the effect of CNV and rare variants on human QTs 3. Expand the number of phenotypes measured in plasma in at least 3,000 examinees (e.g. ILs, etc.) 4. Whole-genome sequence for 1,000 examinees & the new round of consortia participation “Missing heritability”: • CNVs (copy number variants): • Nature (April 2010) – WTCCC – didn’t find any associations with disease at all; • Rare variants: • “Moving frames” method (by Eleftheria Zeggini at Sanger, Hinxton, Cambridge): MAGIC, DIAGRAM & SPIROMETA • “Exome sequencing” (4-10x) • “Deep whole-genome sequencing” (48x) Strategy (5): Next moves (plan for 2010-2012) 1. GWAS of -OMICS (“1 level down from QT”) & functional follow-up & systems biology / pathways 2. Development of novel methods for analysis of the effect of CNV and rare variants on human QTs 3. Expand the number of phenotypes measured in plasma in at least 3,000 examinees (e.g. ILs, etc.) 4. Whole-genome sequence for 1,000 examinees & the new round of consortia participation “Expand phenotypes”: • Gordan: N-glycans • Zoran: CRD series • Tatijana i Vesela: T4, TSH • Mladen: markers of oxidative stress? • Janoš: proteomics? • Rosanda: anti-HBV antigens? • Ana: interleukins, CD4? Strategy (5): Next moves (plan for 2010-2012) 1. GWAS of -OMICS (“1 level down from QT”) & functional follow-up & systems biology / pathways 2. Development of novel methods for analysis of the effect of CNV and rare variants on human QTs 3. Expand the number of phenotypes measured in plasma in at least 3,000 examinees (e.g. ILs, etc.) 4. Whole-genome sequence for 1,000 examinees & the new round of consortia participation “Whole-genome sequence era”: • Wellcome Trust Sanger Institute, Hinxton, Cambridge: agreement that 400 / 2500 first examinees with WGS will be Croatians (Korcula) • Why? – genealogies (expanding the number through “imputation”) and dense phenotyping (hundreds of QTs) • Project will start: end of 2011 • Value for us: GBP 4 million at present time; should get us into the “next wave” of consortia work; needs Vesna Boraska etc.